SCHEMBL701494

SCHEMBL701494

FC(F)(F)c1nnc(Cl)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
ATM Q13315 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MPI P34949 1/20 0.42
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA5A P35218 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
FBP1 P09467 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.37
TAS1R1 Q7RTX1 1/20 0.37
TAS1R2 Q8TE23 1/20 0.37
FFAR2 O15552 1/20 0.36
HTT P42858 6/20 0.34
LMNA P02545 5/20 0.34
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 4/20 0.33
NPC1 O15118 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9509498 0.82 FBP1 (0.37) ALDH1A1ATMMEN1KMT2AMPI
SCHEMBL9505469 0.80 FBP1 (0.36) ALDH1A1ATMMEN1KMT2AFBP1
SCHEMBL31339479 0.80 ALDH1A1 (0.65) ALDH1A1ATMMEN1KMT2AMPI
SCHEMBL9505463 0.77 ALDH1A1 (0.35) ALDH1A1FBP1
SCHEMBL10666440 0.71 FBP1 (0.33) FBP1FFAR2
SCHEMBL6364119 0.69
SCHEMBL5077071 0.68 ALDH1A1 (0.52) ALDH1A1ATMMEN1KMT2AMPI
SCHEMBL5077077 0.68 ALDH1A1 (0.52) ALDH1A1ATMMEN1KMT2AMPI
SCHEMBL7829285 0.68 ALDH1A1 (0.52) ALDH1A1ATMMEN1KMT2AMPI
SCHEMBL5074604 0.68 ALDH1A1 (0.52) ALDH1A1ATMMEN1KMT2AMPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114380771-B Preparation method of flufenacet 浙江财和生物科技有限公司 2023-07-21 CN claimed
CN-114380771-A Preparation method of flufenacet 浙江财和生物科技有限公司 2022-04-22 CN claimed
EP-0094541-B1 SUBSTITUTED 5-TRIFLUOROMETHYL-1,3,4-THIADIAZOL-2-YL OXIACETIC-ACID AMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES BAYER AG (DE) 1987-01-14 EP claimed
EP-0100038-B1 PROCESS FOR THE PREPARATION OF THIADIAZOLOXYACETAMIDES BAYER AG (DE) 1986-03-05 EP claimed
US-4528379-A Preparation of substituted thiadiazolyloxyacetamides BAYER AKTIENGESELLSCHAFT (DE) 1985-07-09 US claimed
EP-0100038-A1 Process for the preparation of thiadiazoloxyacetamides BAYER AG (DE) 1984-02-08 EP claimed
EP-0094541-A2 Substituted 5-trifluoromethyl-1,3,4-thiadiazol-2-yl oxiacetic-acid amides, process for their preparation and their use as herbicides BAYER AG (DE) 1983-11-23 EP claimed
WO-2025120168-A1 SULFONAMIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CRYPTOSPORIDIUM INFECTIONS INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) 2025-06-12 WO disclosed
US-12281102-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-04-22 US disclosed
US-20250034170-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2025-01-30 US disclosed
CN-118994055-A Synthesis method of 2-methylsulfonyl-5-trifluoromethyl-1, 3, 4-thiadiazole 福建永晶科技股份有限公司 2024-11-22 CN disclosed
CN-114340622-B Asparagine Endopeptidase (AEP) inhibitors, compositions and uses related thereto 埃莫里大学 2024-11-01 CN disclosed
EP-4415706-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF Vanqua Bio, Inc. (US) 2024-08-21 EP disclosed
EP-0100038-B1 PROCESS FOR THE PREPARATION OF THIADIAZOLOXYACETAMIDES BAYER AG (DE) 1986-03-05 EP disclosed
EP-0165537-A2 Process for the preparation of heteroaryloxyacetamides BAYER AG (DE) 1985-12-27 EP disclosed
US-4528379-A Preparation of substituted thiadiazolyloxyacetamides BAYER AKTIENGESELLSCHAFT (DE) 1985-07-09 US disclosed
EP-0100038-A1 Process for the preparation of thiadiazoloxyacetamides BAYER AG (DE) 1984-02-08 EP disclosed
EP-0094541-A2 Substituted 5-trifluoromethyl-1,3,4-thiadiazol-2-yl oxiacetic-acid amides, process for their preparation and their use as herbicides BAYER AG (DE) 1983-11-23 EP disclosed
EP-0094541-A2 Substituted 5-trifluoromethyl-1,3,4-thiadiazol-2-yl oxiacetic-acid amides, process for their preparation and their use as herbicides BAYER AG (DE) 1983-11-23 EP disclosed
US-4097669-A FUNGICIDES, BACTERICIDES, INSECTICIDES, ARTHROPODICIDES BAYER AKTIENGESELLSCHAFT (DT) 1978-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12281102-B2 Inhibitors of APOL1 and methods of using same APOL1, APOB, NPC1L1 ALDH1A1 2069/4885ATM 3816/4885MEN1 1767/4885
US-20250034170-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF GBA1, GAA, GBA2 ALDH1A1 1971/4885ATM 3123/4885MEN1 4454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.